Latest Conference Articles

Targeted therapies, CDK4/6 inhibitors, and precision medicine are improving outcomes for patients with high-risk and metastatic disease.

Rising cancer rates and costs pose challenges in global oncology markets amid AI and targeted therapy breakthroughs.

Experts from Moffitt Cancer Center discuss the benefit of multidisciplinary teams in lung cancer care.

The 2024 NCODA International Fall Summit took place in Orlando, Florida, from October 23 to October 25.

This model, which uses technology that discovers black holes, pulls from real data to evaluate cancer treatments, optimizing treatment choices for patients with different cancers.

Liz Vogel, CPhT-Adv, CSPT, discusses the procedures and best practices for safe compounding of hazardous and non-hazardous drugs.

The investigators note that these findings are significant because bile duct cancer is a rare disease with limited treatments and low survival rates.

Glucagon-like peptide-1 (GLP-1) receptor agonists are widely known as treatments for type 2 diabetes, though some have been approved for indications beyond diabetes.

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

Nationally, 7 million women live in maternal health deserts, defined as counties with limited or no available obstetric care.

Changing the way pharmacists and pharmacy staff think about themselves is key, although providers, payers, and patients must also change how they view the value of pharmacy services.

With COVID-19, influenza, respiratory syncytial virus (RSV), and other viruses now circulating, the time for pharmacists to get up to date on the latest vaccine recommendations is now.

Nathan Vanderford, PhD, MBA speaks about barriers to cancer care access experienced by patients in rural communities.

Sara Rogers, PharmD, discusses the formation and goals of the Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) initiative, which seeks to standardize pharmacogenomic practices and improve clinical decision-making by establishing consensus across all stakeholders.

Ryan Nelson, PharmD, discusses the STRIPE Annual Meeting and Consensus Workshop’s focus on unifying pharmacogenetic guidelines across major organizations, such as the FDA, European Medicines Agency, Clinical Pharmacogenetics Implementation Consortium, and National Comprehensive Cancer Network.

Stephanie White, PharmD, CSP, is presenting at the NCODA Fall Summit in Orlando, Florida.

These therapies are being investigated in earlier lines, with several new treatments in development.

Benjamin Brown of Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) discusses his own experience as a patient with cancer and how consensus around pharmacogenomic practices can improve the lives of patients.

Cabotegravir long-acting when used for HIV pre-exposure prophylaxis (PrEP) showed adherence, effectiveness, and improvements in quality of life by those who received the injection.

Ginger Blackmon, PharmD, will discuss enhancing patient cancer care through implementation of medically integrated oncology team and NCODA’s PQI resources.

Pharmacy Times will be at the NCODA Fall Summit in Orlando from October 23 to October 25, 2024.

The guidelines emphasize the importance of vaccination, risk assessment, and preparedness for immunocompromised patients who are traveling post-transplant.

The KEYNOTE-756 and CheckMate 7FL trials show this combination improves pathological complete response rates in this patient population.

Pharmacogenomic testing can help identify patients' genetic profiles, revealing why certain drugs may be less effective or cause adverse effects.

Shirish Gadgeel, MD, discusses an integrated analysis of the regional TRUST-I study and global TRUST-II study presented at the European Society for Medical Oncology Congress 2024.

The FDA faces a multitude of challenges in regulating artificial intelligence (AI) and machine learning (ML) medical devices.

Terry Keys highlights the role of language and terminology as barriers for patients receiving cancer care.

Sarah Hudson-Disalle, PharmD, highlights the significant impact of EHR automation on biosimilar access and costs.